進行肝細胞癌に対するソラフェニブ治療前後の超音波検査所見（非造影/造影）の検討

概要

論文の詳細を見る
To evaluate the sonographic changes observed in hepatocellular carcinoma (HCC) post sorafenib. Sixteen advanced HCC patients received sorafenib and were studied with unenhanced ultrasonography (US) and contrast-enhanced ultrasonography (CEUS) using Sonazoid at before and less than 4 weeks after treatment. Changes in US findings and Micro Flow Imaging (MFI) findings by CEUS were evaluated. MFI findings were classified Fine, Vascular, and Irregular. Response was as follows D (at least a 30%decrease in the major axis of diameters of intratumoral arterial enhancing target lesion) (n=8), I (at least a 20%increase in the minor axis of diameters of intratumoral arterial enhancing target lesion) (n=6), S (other case; stable) (n=2). MFI findings changed Vascular to Fine 3 on D, Fine to Vascular 2, and Vascular to Irregular 2 on I. MFI findings by CEUS are suggested to be useful for evaluating early responses to sorafenib.
一般社団法人　日本肝臓学会の論文